An early‑phase CRISPR‑based gene editing therapy produced substantial reductions in LDL cholesterol and triglycerides in a small cohort of patients, investigators reported. The preliminary dataset—presented at a scientific meeting and published in a major journal—showed durable lipid lowering after a single administration in the initial 15 participants, highlighting the potential for one‑time editing approaches in cardiometabolic disease. Researchers flagged safety signals, particularly possible liver toxicities, and stressed the need for larger trials to confirm efficacy and long‑term tolerability. CRISPR Therapeutics and academic collaborators emphasized the proof‑of‑concept nature of the study and outlined plans for expanded cohorts and refined dosing.